The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis
ConditionTakayasu Arteritis (TAK)
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorChinese SLE Treatment And Research Group
About this trial
This is a 24-week, single-center, randomized, open-label trial conducted by Peking Union Medical College Hospital. The aim of this study is to assess the efficacy and safety of deucravacitinib in adult patients with relapsing TAK in comparison to patients treated with TNF inhibitor (TNFi), the most well-recognized therapeutic choice of non-glucocorticoid immunosuppressive for patients with relapsed or refractory TAK.
Eligibility criteria
Qualifiers
Signed Written Informed Consent
Participants fully understand the purpose, nature, method, and possible adverse reactions of the study, willing to consent to the trial and follow study protocol and sign informed consent.
Participants must have signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines. This ICF must be obtained before performing any protocol related procedures that are not part of normal patient care.
Type of Participant and Target Disease Characteristics
Disqualifiers
Medical Conditions
Severe disease from TAK for which urgent treatment with interventional procedures or bypass surgery is considered necessary
Critical organ involvement of TAK, such as myocardial or coronary artery involvement, or cerebral ischemia
Active hepatitis B or C virus infection, active tuberculosis infection
Trial design
Treatments tested in this trial
- Deucravacitinib
- Adalimumab
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov